Is Big Pharma Out to Stop—Or Take Over—Marijuana Legalization?
Geoffrey Guy stood out when he began attending conferences of the National Organization for the Reform of Marijuana Laws in Washington, DC, in the mid to late 1990s. The stout British gentleman, dressed in a Brooks Brothers suit, was hard to miss among the other attendees dressed in tie-dye shirts and psychedelic parkas, recalled Allen St. Pierre, then NORML’s deputy national director.
But while he might not have fit in, Guy, a doctor in his early 40s who’d already made millions by founding a UK-based pharmaceutical company, was eager to learn all he could at the events about medical marijuana.
“He was like a dry sponge who desperately wanted to be thrown in a bucket of water,” said St. Pierre, who recently resigned from his 11-year stint as NORML’s executive director to pursue private-sector opportunities.
What Guy absorbed at those conferences and other fact-finding excursions became the basis...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin